Oct 20, 2024 · Regenerative treatment including low-intensity shockwave therapy (LiWST) and platelet-rich plasma (PRP) injections, as well as a combination of both, may be efficacious for the treatment of erectile dysfunction (ED).. In new systematic review and meta-analysis data presented at the Sexual Medicine Society of North America (SMSNA) 2024 Fall Scientific Meeting in Scottsdale, AZ this week, a team ...

Jan 1, 2025 · The FDA granted full approval to erdafitinib (Balversa) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least 1 line of prior systemic therapy, according to the FDA.The treatment is not recommended for patients who have not received treatment with PD-1/PD-L1 ...

Jun 23, 2024 · In this interview, Jason M. Hafron, MD, discusses how IsoPSA, a blood test for the assessment of risk for high-grade prostate cancer, fits into the current diagnostic and treatment landscape.Hafron also highlights key findings from the study, “Using IsoPSA With Prostate Imaging Reporting and Data System Score May Help Refine Biopsy Decision Making in Patients With Elevated PSA.” 1

Oct 19, 2024 · Discussing the background for the study, investigator Olivia Paulsen told Urology Times, “We know that [BPH] has an association with lower urinary tract symptoms, but its relationship to erectile dysfunction has not been explored in the same depth.That's exactly what our study sought to explore.” Paulsen is a medical student at Idaho College of Osteopathic Medicine in Meridian, Idaho.

Apr 7, 2023 · The current study is welcome news as it lends further support to the use of intravesical Gem/Doce as a safe and effective option that has the potential to become a new standard of care for high-risk NMIBC.

Nov 28, 2024 · In this video, Eric Li, MD, shares the take-home message from The Journal of Urology paper “Clinical Factors Associated with Suspicious 18F-DCFPyL PSMA PET Activity in Patients Initially Managed with Radical Prostatectomy including PSA <0.5 ng/mL.” Li is a urology resident at Northwestern University Feinberg School of Medicine in Chicago, Illinois.

Jan 9, 2025 · A panelist discusses how emerging investigational agents for NMIBC show promise through diverse mechanisms, including oncolytic viruses (CG0070), immune checkpoint inhibitors (durvalumab, sasanlimab), targeted drug delivery systems (TAR-200), mitomycin-containing gels (UGN-102/103), immunotherapies (TARA-002), gene therapies (EG-70), and FGFR inhibitors (erdafitinib), representing a robust ...

Dec 28, 2024 · In this video, Helen Y. Hougen, MD, shares the background and findings from the study, “Adding a Coefficient for Race to the 4Kscore Improves Calibration for Black Men.” Watch the video here. Dr. Murphy on increasing diversity in cancer clinical trials. In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing ...

Apr 30, 2023 · Vibegron (Gemtesa) and mirabegron (Myrbetriq) demonstrated similar efficacy and safety in a comparative study of the 2 treatments in female patients with overactive bladder (OAB); however, more patients preferred vibegron, according to a study presented at the 2023 AUA Annual Meeting. 1

Sep 12, 2018 · Dr. Parsons is professor of urology, division of urologic oncology, department of urology, Moores UCSD Comprehensive Cancer Center, La Jolla, CA.. Patients have become voracious consumers of the medical literature. Each week, a flurry of new urology studies surface in the popular media to feed public interest.